CDSCO approval FDC medicines has been conditionally granted for the manufacture and sale of five such medicines in India.
- The Union health ministry had previously banned 14 FDC drugs, citing a lack of therapeutic justification.
Key Highlights of the approval:
- The CDSCO issued an order for conditional approval of five FDC medicines.
- Manufacturers are required to provide post-marketing safety and efficacy data for three of these combinations.
Specific Instructions:
- For combinations used in treating cold and allergy symptoms (e.g., paracetamol, phenylephrine hydrochloride, caffeine anhydrous), manufacturers must submit safety and efficacy data within one year.
- For the second FDC, companies are instructed to conduct randomised comparative phase IV clinical trials.
- The order specifies that phase IV clinical trials are mandatory for generating data within a year.
Additional Combinations and Regulations:
- The combination of imipramine hydrochloride + diazepam must be indicated for comorbid anxiety conditions, with treatment duration not exceeding 6 to 8 weeks.
- Chlorpheniramine maleate + ammonium chloride + sodium citrate, used for treating cough with mucus, must follow specified dose strengths and schedules for adults and children, ensuring doses do not exceed the maximum permissible limit.
Regulatory Oversight:
- The CDSCO’s directive aims to standardize the manufacture of these FDCs, ensuring efficacy, safety, and correct dosage information.
- This move signifies increased scrutiny and regulation of pharmaceutical products to ensure public health safety.
What are Fixed-Dose Combination Medicines (FDCs)?
- Fixed-dose combination Medicines (FDCs) refer to pharmaceutical formulations that contain two or more active ingredients in a fixed ratio of doses within a single dosage form.
The rationale for FDCs:
- Enhanced Efficacy: Combining multiple active ingredients can lead to increased therapeutic efficacy.
- Improved Compliance: Simplifies drug regimens, enhancing patient adherence to treatment.
- Synergistic Effects: Allows for synergies between different drugs to address multiple aspects of a disease.
Challenges and Concerns:
- Lack of Evidence: Some FDCs may lack robust clinical evidence supporting their efficacy and safety.
- Risk of Polypharmacy: Increased risk of adverse effects and drug interactions with multiple active ingredients.
Resistance Concerns: Overuse of FDCs may contribute to antimicrobial resistance
Ref: Source
| UPSC IAS Preparation Resources | |
| Current Affairs Analysis | Topperspedia |
| GS Shots | Simply Explained |
| Daily Flash Cards | Daily Quiz |